マルチプレックスアッセイの世界市場：2023-2030年

マルチプレックスアッセイの世界市場は、予測期間（2023-2030年）にCAGR 14.8％で成長すると予測されます。市場の成長は、免疫療法の進歩の増加に起因しています。がん治療における免疫療法、特にキメラ抗原受容体（CAR）T細胞療法の使用が増加しているため、CAR-T細胞の正確な測定とモニタリングの必要性が高まっています。マルチプレックスデジタルPCRアッセイは、治療の成功判定に必要な正確で包括的な分析を提供することで、この需要を満たしています。例えば、2023年6月、BioPharma Services, Inc.は、特定のがんを認識し破壊するためにT細胞を遺伝子改変することを含むがん免疫療法の一種である複数のCAR-T細胞の包括的定量化のための新しいマルチプレックスデジタルPCRアッセイを発売しました。この分析法はQiagen QIAcuity digital PCR手法に基づいており、独自のナノプレート手法によりパワフルかつシンプルなデジタルPCR体験を提供します。

セグメント別の展望

マルチプレックスリアルタイムPCRサブセグメントが世界のマルチプレックスアッセイ市場でかなりのシェアを占めると予測されます。

技術の中で、マルチプレックスリアルタイムPCRサブセグメントが世界のマルチプレックスアッセイ市場でかなりのシェアを占めると予想されています。このセグメントの成長は、検査効率の向上に起因しています。マルチプレックスアッセイは、1回のレスポンスで複数のターゲットを検出することで検査を簡素化します。1回の反応で2つのN遺伝子ターゲット配列を認識できるため、検査時間が短縮され、スループットが向上し、診断ラボの効率が高まる。例えば、2020年5月、Gold Standard Diagnostics社はSARS-CoV-2用のMultiplex Real-Time PCR Assayを発表しました。GSD NovaPrime SARS-CoV-2（COVID-19）はSARS-CoV-2を検出するためにデザインされたリアルタイムPCR検査です。1回の反応でN遺伝子の2つの標的配列を検出するマルチプレックステストで、2時間で結果が得られます。試薬には抽出/阻害コントロールと陽性コントロールが含まれます。

地域別展望

北米は、慢性疾患や感染症に罹患する人が増加していることに加え、マルチプレックスアッセイ製品やサービスの利用に対する認識が高まっていることから、世界市場で突出したシェアを占めると予想されます。

北米地域は世界のマルチプレックスアッセイ市場において著しいCAGRで成長する見込み

すべての地域の中で、北米地域は予測期間中にかなりのCAGRで成長すると予測されています。この地域の成長は、パンデミックへの備えとサーベイランスに起因しています。COVID-19パンデミック時に、先行感染を検出し、集団曝露率を追跡するために、正確で効率的な血清学的アッセイが緊急に必要とされていることが、主要な推進要素となっています。この血清学的アッセイのような高い特異性と感度を持つ多重アッセイは、集団レベルのサーベイランスに不可欠です。米国立衛生研究所（NIH.gov）によると、2022年1月、血清学的COVID-19マルチプレックスアッセイが開発され、回復者と未感染者の2つのグループの血清サンプルを用いて検証されました。複数の抗原候補を試験した結果、SARS-CoV-2ヌクレオカプシドタンパク質（NP）とスパイクタンパク質の受容体結合ドメイン（RBD）がヒトCOVID-19マルチプレックスアッセイ用に選択されました。合成されたRBDタンパク質と哺乳類で発現されたRBDタンパク質の比較から、哺乳類発現の利点が示されました。NPおよびRBD特異的IgGおよびIgAの検出は、コントロールと患者を区別するのに優れた性能（AUC >0.90）を示し、IgGアッセイはより広いダイナミックレンジを有していました。このアッセイ法は、ニューヨーク州イサカの低発生率地域に住む人々のSARS-CoV-2に対する血清有病率を評価するために使用されました。2020年にサンプリングされた332人の健康なボランティアのうち、1.2-5.7%がNPまたはRBDのいずれかに陽性であり、これは郡が報告した罹患率0.16%よりも高かったです。この検査法は、地域社会での曝露率や、感染またはワクチン接種後の免疫反応の持続期間をモニターするために使用できます。

目次

第1章 レポート概要

• 業界の現状分析と成長ポテンシャルの展望
• 調査方法とツール
• 市場内訳
  • セグメント別
  • 地域別

第2章 市場概要と洞察

• 調査範囲
• アナリストの洞察と現在の市場動向
  • 主な調査結果
  • 推奨事項
  • 結論

第3章 競合情勢

• 主要企業分析
• Abcam plc
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Agilent Technologies
  • 会社概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• BioMerieux SA
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• 主要戦略分析

第4章 市場セグメンテーション

• マルチプレックスアッセイの世界市場：タイプ別
  • タンパク質のマルチプレックスアッセイ
  • 核酸ベースのマルチプレックスアッセイ
  • 細胞ベースのマルチプレックスアッセイ
• マルチプレックスアッセイの世界市場：技術別
  • マルチプレックスリアルタイムPCR
  • ルミネックスビーズテクノロジー
  • フローサイトメトリー
  • その他（次世代シーケンス（NGS）、マイクロアレイ技術）
• マルチプレックスアッセイの世界市場：エンドユーザー別
  • 製薬会社およびバイオ医薬品会社
  • 開発業務受託機関（CRO）
  • 研究・学術機関
  • その他（バイオテクノロジーおよび製薬会社、臨床診断ラボ）

第5章 地域別分析

• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • イタリア
  • スペイン
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 世界のその他の地域

第6章 企業プロファイル

• Bio-Rad Laboratories, Inc.
• Bio-Techne Corp.
• BioTools Inc.
• CareDx, Inc.
• Diasorin S.p.A.
• Hologic, Inc.
• Illumina, Inc.
• Merck Group
• Meso Scale Diagnostics, LLC
• PerkinElmer U.S. LLC
• Promega Corp.
• QIAGEN GmbH
• Quansys Biosciences Inc.
• Randox Laboratories
• Seegene, Inc.
• Thermo Fisher Scientific Inc.

LIST OF TABLES

• 1. GLOBAL MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
• 2. GLOBAL PROTEIN MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 3. GLOBAL NUCLEIC ACID-BASED MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 4. GLOBAL CELL-BASED MULTIPLEX ASSAYS RESEARCH MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 5. GLOBAL MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
• 6. GLOBAL MULTIPLEX ASSAYS BY MULTIPLEX REAL-TIME PCR MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 7. GLOBAL MULTIPLEX ASSAYS BY LUMINEX BEAD TECHNOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 8. GLOBAL MULTIPLEX ASSAYS BY FLOW CYTOMETRY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 9. GLOBAL MULTIPLEX ASSAYS BY OTHER TECHNOLOGIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 10. GLOBAL MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
• 11. GLOBAL MULTIPLEX ASSAYS FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 12. GLOBAL MULTIPLEX ASSAYS FOR CONTRACT RESEARCH ORGANIZATIONS (CRO) MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 13. GLOBAL MULTIPLEX ASSAYS FOR RESEARCH AND ACADEMIC INSTITUTIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 14. GLOBAL MULTIPLEX ASSAYS FOR OTHER END-USERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 15. GLOBAL MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 16. NORTH AMERICAN MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 17. NORTH AMERICAN MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
• 18. NORTH AMERICAN MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
• 19. NORTH AMERICAN MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
• 20. EUROPEAN MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 21. EUROPEAN MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
• 22. EUROPEAN MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
• 23. EUROPEAN MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
• 24. ASIA-PACIFIC MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 25. ASIA-PACIFIC MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
• 26. ASIA-PACIFIC MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
• 27. ASIA-PACIFIC MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
• 28. REST OF THE WORLD MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 29. REST OF THE WORLD MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
• 30. REST OF THE WORLD MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
• 31. REST OF THE WORLD MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)

LIST OF FIGURES

• 1. GLOBAL MULTIPLEX ASSAYS MARKET SHARE BY TYPE, 2022 VS 2030 (%)
• 2. GLOBAL PROTEIN MULTIPLEX ASSAYS MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 3. GLOBAL NUCLEIC ACID-BASED MULTIPLEX ASSAYS MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 4. GLOBAL CELL-BASED MULTIPLEX ASSAYS RESEARCH MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 5. GLOBAL MULTIPLEX ASSAYS MARKET SHARE BY TECHNOLOGY, 2022 VS 2030 (%)
• 6. GLOBAL MULTIPLEX ASSAYS BY MULTIPLEX REAL-TIME PCR MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 7. GLOBAL MULTIPLEX ASSAYS BY LUMINEX BEAD TECHNOLOGY MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 8. GLOBAL MULTIPLEX ASSAYS BY FLOW CYTOMETRY MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 9. GLOBAL MULTIPLEX ASSAYS BY OTHER TECHNOLOGIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 10. GLOBAL MULTIPLEX ASSAYS MARKET SHARE BY END-USER, 2022 VS 2030 (%)
• 11. GLOBAL MULTIPLEX ASSAYS FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 12. GLOBAL MULTIPLEX ASSAYS FOR CONTRACT RESEARCH ORGANIZATIONS (CRO) MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 13. GLOBAL MULTIPLEX ASSAYS FOR RESEARCH AND ACADEMIC INSTITUTIONS MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 14. GLOBAL MULTIPLEX ASSAYS FOR OTHER END-USERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 15. GLOBAL MULTIPLEX ASSAYS MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 16. US MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
• 17. CANADA MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
• 18. UK MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
• 19. FRANCE MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
• 20. GERMANY MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
• 21. ITALY MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
• 22. SPAIN MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
• 23. REST OF EUROPE MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
• 24. INDIA MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
• 25. CHINA MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
• 26. JAPAN MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
• 27. SOUTH KOREA MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
• 28. REST OF ASIA-PACIFIC MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
• 29. REST OF THE WORLD MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)

Global Multiplex assays Market Size, Share & Trends Analysis Report by Type (Protein Multiplex Assays, Nucleic Acid-Based Multiplex Assays, and Cell-based Multiplex Assays), by Technology (Multiplex Real-Time PCR, Luminex Bead Technology, Flow Cytometry, and Others), and by End-User (Pharmaceutical and Biopharmaceutical Companies, Contract Research Organizations (CROs), Research and Academic Institutions, Others), Forecast Period (2023-2030)

The global multiplex assays market is anticipated to grow at a CAGR of 14.8% during the forecast period (2023-2030). The market's growth is attributed to the increasing advancements in immunotherapy. The increased use of immunotherapy, particularly chimeric antigen receptor (CAR) T cell therapy, for cancer treatment increases the need for accurate measurement and monitoring of CAR-T cells. Multiplex digital PCR assays satisfy the demand by delivering accurate, comprehensive analysis necessary for determining therapy success. For instance, in June 2023, BioPharma Services, Inc., launched new multiplex digital PCR assays for comprehensive quantification of multiple CAR-T cells, a type of cancer immunotherapy that involves genetically modifying T-cells to recognize and destroy certain cancers. The analysis is based on the Qiagen QIAcuity digital PCR methodology, that offers a powerful yet simple digital PCR experience with its unique nanoplate methodology.

Segmental Outlook

The global multiplex assays market is segmented on the type, technology, and end-user. Based on the type, the market is sub-segmented into protein multiplex assays, nucleic acid-based multiplex assays, and cell-based multiplex assays. Based on the technology, the market is sub-segmented into multiplex real-time PCR, Luminex bead technology, flow cytometry, and others. Further, based on the end-user, the market is sub-segmented into pharmaceutical and biopharmaceutical companies, CROs, research and academic institutions, and others. Among the type, the nucleic acid-based multiplex assays subcategory is expected to capture a significant portion of the market share. This is attributed to the increase in the usage of nucleic acid-based multiplex assays and research on nucleic acid-based multiplex assays.

The Multiplex Real-Time PCR Sub-Segment is Anticipated to Hold a Considerable Share of the global Multiplex assays Market

Among the technology, the multiplex real-time PCR sub-segment is expected to hold a considerable share of the global multiplex assays market. The segmental growth is attributed to the enhanced testing efficiency. Multiplex assays simplify testing by detecting several targets in a single response. The capacity to recognize two N-gene target sequences in a single reaction decreases testing time, boosts throughput, and enhances diagnostic laboratory efficiency. For instance, in May 2020, Gold Standard Diagnostics Launched Multiplex Real-Time PCR Assay for SARS-CoV-2. GSD NovaPrime SARS-CoV-2 (COVID-19) is a real-time PCR test designed to detect SARS-CoV-2. It is a multiplex test which detects two target sequences of the N-gene in one reaction, providing results in 2 hours. The reagents include an extraction/ inhibition control and a positive control.

Regional Outlook

The global multiplex assays market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, North America is anticipated to hold a prominent share of the market around the globe, owing to the increasing number of individuals suffering from chronic and infectious diseases, in addition to increased awareness of the usage of multiplex assay products and services.

The North America Region is Expected to Grow at a Significant CAGR in the global Multiplex Assays Market

Among all regions, the North America region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the pandemic preparedness and surveillance. A primary driving element is the urgent need for precise and efficient serological assays to detect prior infections and track population exposure rates during the COVID-19 pandemic. Multiplex assays with high specificity and sensitivity, such as this serological assay, are essential in population-level surveillance. According to the National Institute of Health (NIH.gov), in January 2022, a serological COVID-19 multiplex assay was developed and validated using serum samples from 2 groups of recovered people; and those who had not yet been infected. After testing multiple potential antigens, the SARS-CoV-2 nucleocapsid protein (NP) and receptor-binding domain (RBD) of the spike protein were selected for the human COVID-19 multiplex assay. A comparison of synthesized and mammalian expressed RBD proteins showed the advantages of mammalian expression. Detection of NP and RBD specific IgG and IgA had excellent performance (AUC > 0.90) for distinguishing patients from controls, with the IgG assay having a wider dynamic range. This assay was used to evaluate seroprevalence to SARS-CoV-2 in people living in a low-incidence community in Ithaca, NY. Of the 332 healthy volunteers sampled 2020, 1.2-5.7% tested positive for either NP or RBD, which was higher than the county's reported incidence rate of 0.16%. This assay can be used to monitor community exposure rates and the duration of immune response following infection or vaccination.

Market Players Outlook

The major companies serving the global multiplex assays market include Bio-Rad Laboratories, Inc., Merck Group, PerkinElmer U.S. LLC, Quansys Biosciences Inc., Thermo Fisher Scientific Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in July 2023, EDP Biotech merged with New Day Diagnostics to form a vertically integrated diagnostic company to advance the development and commercialization of diagnostic tests. EDP offers the ColoPlex in vitro diagnostic assay, that assists in the early detection of pre-cancerous cancer polyps and colorectal cancer.

The Report Covers:

• Market value data analysis of 2022 and forecast to 2030.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global multiplex assays market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies. Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Region

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
• 3.2. Abcam plc
  • 3.2.1. Overview
  • 3.2.2. Financial Analysis
  • 3.2.3. SWOT Analysis
  • 3.2.4. Recent Developments
• 3.3. Agilent Technologies
  • 3.3.1. Overview
  • 3.3.2. Financial Analysis
  • 3.3.3. SWOT Analysis
  • 3.3.4. Recent Developments
• 3.4. BioMerieux SA
  • 3.4.1. Overview
  • 3.4.2. Financial Analysis
  • 3.4.3. SWOT Analysis
  • 3.4.4. Recent Developments
• 3.5. Key Strategy Analysis

4. Market Segmentation

• 4.1. Global Multiplex Assays Market by Type
  • 4.1.1. Protein Multiplex Assays
  • 4.1.2. Nucleic Acid-Based Multiplex Assays
  • 4.1.3. Cell-based Multiplex Assays
• 4.2. Global Multiplex Assays Market by Technology
  • 4.2.1. Multiplex Real-Time PCR
  • 4.2.2. Luminex Bead Technology
  • 4.2.3. Flow Cytometry
  • 4.2.4. Others (Next-Generation Sequencing (NGS), and Microarray Technology)
• 4.3. Global Multiplex Assays Market by End-User
  • 4.3.1. Pharmaceutical and Biopharmaceutical Companies
  • 4.3.2. Contract Research Organizations (CROs)
  • 4.3.3. Research and Academic Institutions
  • 4.3.4. Others (Biotechnology and Pharmaceutical Companies, and Clinical Diagnostics Labs)

5. Regional Analysis

• 5.1. North America
  • 5.1.1. United States
  • 5.1.2. Canada
• 5.2. Europe
  • 5.2.1. UK
  • 5.2.2. Germany
  • 5.2.3. Italy
  • 5.2.4. Spain
  • 5.2.5. France
  • 5.2.6. Rest of Europe
• 5.3. Asia-Pacific
  • 5.3.1. China
  • 5.3.2. India
  • 5.3.3. Japan
  • 5.3.4. South Korea
  • 5.3.5. Rest of Asia-Pacific
• 5.4. Rest of the World

6. Company Profiles

• 6.1. Bio-Rad Laboratories, Inc.
• 6.2. Bio-Techne Corp.
• 6.3. BioTools Inc.
• 6.4. CareDx, Inc.
• 6.5. Diasorin S.p.A.
• 6.6. Hologic, Inc.
• 6.7. Illumina, Inc.
• 6.8. Merck Group
• 6.9. Meso Scale Diagnostics, LLC
• 6.10. PerkinElmer U.S. LLC
• 6.11. Promega Corp.
• 6.12. QIAGEN GmbH
• 6.13. Quansys Biosciences Inc.
• 6.14. Randox Laboratories
• 6.15. Seegene, Inc.
• 6.16. Thermo Fisher Scientific Inc.